What Slice treats: main uses and benefits

The specialized veterinary preparation Slice (Emamectin Benzoate) is applied across therapeutic domains involving certain distressing symptoms caused by external parasitic infestations and is relevant in contexts marked by increased discomfort or tension in finfish populations.

The product is indicated for the treatment and prevention at group level of infestations of all parasitic stages of sea lice (Lepeophtheirus sp. and Caligus sp.) in Atlantic Salmon.

---

Managing Ectoparasitic Infestations in Farmed Fish

This medication is commonly used to address conditions involving infestations of crustacean ectoparasites, primarily sea lice, which are common in farmed salmon. It is applied in clinical settings that involve acute or unstable symptom patterns where parasite loads are considered relevant. It is used to help address symptom clusters that may become intense or disruptive on the host, and the treatment provides supportive relief when symptoms interfere with routine activities.

Easing Physical Damage and Supporting Stock Health

The key therapeutic use is the management of symptom clusters resulting from the parasite’s feeding and attachment, including skin lesions, gill damage, and the risk of secondary infections. Management of the parasitic source may assist with managing symptoms related to systemic imbalance and noticeable physiological strain, such as reduced growth rates and lethargy. This action supports patients during episodes of heightened discomfort and contributes to improved comfort and supports general well-being during symptomatic phases.

“The therapy is commonly used to help manage the discomfort and physical compromise caused by the parasitic burden.”

---

Quick Fact: Management for Symptoms Related to Irritation and Systemic Strain

Quick Fact: Management for Symptoms Related to Irritation and Systemic Strain

Regulatory References

1. UK Veterinary Medicines Directorate Product Information

The eligibility profile for Slice (Emamectin Benzoate) is strictly defined by regulatory bodies for use in Atlantic Salmon across commercial life stages, from smolts up to market-size fish. This usage is conditional on the fish population actively feeding.

Contraindications and Prohibited Populations

Official regulatory documents state that the medicine must not be used in specific populations. Use is contraindicated for adult Atlantic Salmon intended for broodstock (breeding stock), as data on reproductive safety is not available. The product is also contraindicated for smolts housed in freshwater cages; juvenile fish are only eligible for treatment when housed in tanks or flowing waterways.

Restrictions and Limited Eligibility

Eligibility requires special consideration for fish with concurrent infectious diseases or severe skin lesions, as use may carry an increased risk of mortality in compromised animals. The population is also subject to regulatory use history constraints: the medicine must not be administered more than once in the 60 days prior to the first fish being harvested to comply with mandated residue limits.

The official regulatory profile for the veterinary antiparasitic Slice (Emamectin Benzoate) is characterized by specific constraints regarding administration and a documented lack of known systemic interactions. Official government documentation addresses the product’s interaction profile primarily through administrative restrictions rather than complex metabolic pathways.

---

Interaction scope

Category	Official Regulatory Status / Specific Entity
Medicinal product categories with documented interactions:	None formally documented as having systemic interaction with the active ingredient.
Mechanistic basis of interactions:	No specific pharmacokinetic (PK) or pharmacodynamic (PD) mechanisms of interaction are documented in the regulatory label.
Timing-based interaction rules (if applicable):	The product must not be mixed with other veterinary medicinal products.
Interaction-related restrictions:	Mandatory prohibition on co-administration via mixing.

---

Interaction classifications (high-level)

Category	Classification Details
Interaction severity classification:	No known systemic clinically significant interactions are documented.
Regulatory basis:	UK Veterinary Medicines Directorate (VMD) Summary of Product Characteristics (SmPC).
Interaction-context constraints:	Must be administered as a single agent; co-mixing is explicitly restricted by regulatory documents.

---

Resulting interaction structure

Official interaction statements:

• The official regulatory profile states that no systemic interactions are known with other medicinal products.
• Compatibility studies are absent, leading to the requirement that the product must not be mixed with any other veterinary medicinal product.

Connection to the overall interaction profile (2–4 sentences): The official regulatory documentation establishes the interaction structure primarily by the stated lack of known systemic drug-drug interactions. The main documented constraint is a procedural restriction which prohibits mixing the product with other medicinal products due to a lack of formulation compatibility data, mandating strict physical separation during administration.

The mechanism of action for the active ingredient, Emamectin Benzoate, is focused exclusively on disrupting the neurotransmission of target parasites, primarily crustacean copepods. This action is achieved through highly specific molecular targeting that leads to the functional collapse of the parasite's motor system.

---

Selective Targeting of Invertebrate Chloride Channels

The drug acts within domains involving receptor-mediated signaling by binding to and allosterically modulating Glutamate-Gated Chloride Channels (GluCl). These channels are prevalent in the parasite's nervous tissue but are structurally distinct from those in the host fish, which reflects the differential mechanism across species. This binding forces the channel to remain continuously open, leading to an excessive influx of chloride ions.

---

Neuronal Hyperpolarization and Neuromuscular Blockade

This continuous chloride influx modifies early molecular steps that shape systemic physiological outcomes. The nerve cell is driven into a state of hyperpolarization, making it electrically unresponsive and incapable of firing action potentials or transmitting signals. This profound and sustained inhibition halts the flow of motor commands to the muscles, resulting in irreversible flaccid paralysis of the parasite. This physiological outcome prevents the parasite from feeding or attaching, which is the final physiological consequence of the mechanism.

How to Use Slice (Emamectin Benzoate)

Slice is an oral formulation for Atlantic Salmon, and its usage is defined by established protocols concerning dose, duration, and administration. The medication is administered systemically via medicated feed, requiring specialized preparation that is typically managed only at **commercial fish feed mills.

---

Official Administration Protocol

Feature	Official Instruction
Route of Administration	Oral, via medicated feed
Standard Daily Dose	50 micrograms/kg of fish biomass per day (50 mu g/kg/day)
Treatment Duration	Seven consecutive days
Frequency Pattern	Once daily; used as an intermittent therapy

---

Administration and Use Constraints

The target dose of 50 mu g/kg/day is achieved by carefully controlling the concentration of the premix within the feed, relative to the fish's feeding rate (e.g., 0.5% of biomass per day). If the actual feeding rate differs, the concentration of the drug in the feed is adjusted proportionately to maintain the correct daily dose. The premix must be coated onto the feed pellets using oil to ensure adherence before administration.

Usage of Slice is subject to clear time constraints: the treatment course lasts 7 days and is limited to a maximum of 5 treatments per two-year growth cycle, and not more than 3 per 12-month period. Furthermore, the drug is restricted from use in adult Atlantic Salmon intended for broodstock. To maximize the procedural effectiveness, the treatment of all fish on a site, and coordination with nearby farms, is commonly recommended.

Research evidence / Overview of Studies for Slice

Evidence for Use in Managing Sea Lice Infestations in Farmed Finfish

Studies were conducted to explore the use of this medicine in aquaculture settings, focusing on research examining external parasites known as sea lice (Lepeophtheirus and Caligus species) on cultured fish populations. The core research effort includes short-term Randomized Controlled Trials (RCTs) and various observational field studies. These research efforts primarily examined outcomes related to the mean number of sea lice counted per fish over a defined time interval after treatment.

In these studies, the research examined fish populations, mainly Atlantic Salmon, that were experiencing natural parasite burdens in their net-pen environments. The administration of medicated feed was observed in these settings over a short, defined period. Research highlights changes measured during the study period in the treated groups. These studies contribute to the research context regarding group patterns, not personal outcomes for any specific fish population.

Long-Term Research and Durability of Observed Effects

Research has explored the durability of the observed changes in sea lice populations over time following the treatment period. The follow-up durations were limited in initial trials, primarily focusing on immediate and intermediate changes over a few weeks. However, long-term effects are not fully established regarding the sustained control over a full, long-duration commercial cycle.

Study Populations and Contextual Differences

The majority of the foundational research was conducted using Atlantic Salmon populations, which are the primary host species for these parasites in aquaculture. Studies also explored use in other species, such as Rainbow Trout and Hybrid Grouper, though data for certain groups remain insufficient. Findings documented variability that may correlate with environmental factors like water temperature or differences in local parasite prevalence.

What Is Still Uncertain and Research Gaps

Certainty remains low in areas where findings were mixed, particularly when reviewing outcomes across diverse geographical areas over several years. This means that data are still emerging regarding the consistent patterns across all global aquaculture regions. Ongoing research includes evaluating how sea lice populations may develop a lower sensitivity or resistance to the active ingredient. As noted, since study results reflect the specific conditions under which they were conducted, research does not provide certainty about whether an individual farm will observe similar patterns.

Key Studies & References UK Veterinary Medicines Directorate Product Information - SLICE

Common questions about Slice (FAQ)

---

Q: Why is Slice prescribed instead of other similar medicines?

Official research and development documents indicate that the active ingredient in Slice, Emamectin Benzoate, was developed due to its specific activity against the target parasite. This was based on studies evaluating its use compared to other related medicines in the same class (avermectins).

Q: How quickly does Slice start to work after the first dose?

Studies on the mechanism of action show that once the medicine is taken up by the target parasite, it begins to disrupt the nerve signals. This disruption is associated with irreversible flaccid paralysis of the parasite, which prevents it from feeding or attaching to the host.

Q: Can taking Slice cause weight gain or weight loss?

Safety studies conducted in the target species, Atlantic Salmon, have noted a slight reduction in appetite in some cases during the seven-day period of medication. Official product information does not indicate weight gain or weight loss as a primary expected physiological outcome of the treatment itself.

Q: Is it true that Slice can affect your mood?

The official safety profile focuses on the target animal (Atlantic Salmon) and occupational risks for human handlers. The information available for the target animal does not list behavioral changes or effects on mood when used at the standard recommended treatment concentration.

Q: Is Slice available over the counter, or is it prescription only?

According to the official product information, Slice is classified as a restricted veterinary product. Regulatory classification indicates that it is a restricted product, available through an authorized animal prescriber or veterinary surgeon.

Q: Is there a generic version of Slice available?

Corporate regulatory filings sometimes reference market risks related to intellectual property. These documents mention the potential for generic versions of the product to become available after the existing patent exclusivity period ends.

Q: Are there any specific lifestyle changes recommended when using Slice?

The manufacturer offers technical support programs for professionals using the product. These programs provide training and guidance on best practices to support administration and optimal use of the medicine.

Q: Is there a patient support program associated with Slice?

The manufacturer offers a comprehensive technical support program for professionals and veterinarians using the product. These services include analysis of the medicated feed, testing for parasite sensitivity before treatment, and evaluating tissue clearance after the treatment course is finished.

Q: How long after starting Slice can I expect to notice changes?

Research into the duration of observed effect in controlling the parasite population has noted that the time frame can be up to 10 weeks following the administration of the medicine.

Q: How long does Slice stay in your system after you stop taking it?

Pharmacokinetic studies were conducted in Atlantic Salmon to determine how the body processes the medicine. These studies describe the elimination half-life of the active ingredient in the fish's muscle and skin tissue as approximately 10 to 11 days.

The storage and disposal of Slice (Emamectin Benzoate) must adhere strictly to regulatory requirements to ensure product stability and environmental safety.

Official Storage Conditions

The premix must be stored in its original laminate foil pouch at temperatures between 2 C and 30 C. The product is stable for 3 years when stored unopened. Once the premix is incorporated into meal or pelleted feed, the stability period reduces to 6 months. The label mandates storage out of the sight and reach of children.

Disposal and Environmental Protection

Due to the active ingredient's toxicity to aquatic organisms, the product should not enter water courses and must not be disposed of via wastewater or household waste. Unused or expired materials must be disposed of in accordance with national requirements, typically utilizing official take-back schemes.